Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01073384 · ClinicalTrials.gov registry record · Phase 1
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
A Phase 1 study, sponsored by Soligenix.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01073384 is a Phase 1 study that has completed, run by Soligenix. The registered enrollment target is 16 participants.
The verdict
NCT01073384, a Phase 1 study, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.
Interventions
- DRUG SGX201 (delayed release beclomethasone 17,21-dipropionate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01073384
The ClinicalTrials.gov registry entry for NCT01073384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGX201 (delayed release beclomethasone 17,21-dipropionate) is the first listed.
NCT01073384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01073384 about?
NCT01073384 is a clinical study titled "A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer". The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.
What is the current status of trial NCT01073384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01073384?
The interventions under investigation include: SGX201 (delayed release beclomethasone 17,21-dipropionate) (DRUG).
Who is sponsoring clinical trial NCT01073384?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.